Welcome to the e-CCO Library!

OP025: Escalation of medical therapy decreases need for repeat dilatation in Crohns anastomatic strictures
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

N. S. Ding*1, 2, W. Yip1, R. Choi1, B. Saunders3, S. Thomas-Gibson3, N. Arebi1, A. Humphries3, A. Hart1

Created: Friday, 22 February 2019, 9:49 AM
OP025: Evaluation of adalimumab effectiveness in anti-tumor necrosis factor-naïve pediatric patients with Crohn's disease in clinical practice
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Steiner S.*1, King E.2, Park K.3, Pashankar D.4, Shashidhar H.5, Sudel B.6, Eichner S.7, Chen S.2, Pratt J.2, Colletti R.8 ImproveCareNow Network, Burlington, United States

Created: Wednesday, 20 February 2019, 10:36 AM
OP025: Evaluation of adalimumab effectiveness in anti-tumor necrosis factor-naïve pediatric patients with Crohn’s Disease in clinical practice
Year: 2017
Source: ECCO'17 Barcelona
Authors: Steiner S.
Last Modified: Wednesday, 15 March 2017, 2:24 PM by ECCO Administrator
Crohn's disease, Disease activity Indices, Adalimumab
Files: 1
OP026: Comparative effectiveness of vedolizumab and TNF-antagonist therapy in ulcerative colitis: a multicentre consortium propensity score-matched analysis
Year: 2018
Source: ECCO '18 Vienna
Authors:

D. Faleck1, P. Shashi2, J. Meserve3, M. Rahal4, S. Kadire4, G. Tran4, A. Weiss5, A. Winters1, S. Chablaney1, S. Aniwan6, J.L. Koliani-Pace7, G. Kochhar2, B. Boland3, S. Singh3, R. Hirten1, E. Shmidt1, K. Lasch8, M. Luo8, M. Bohm4, S. V Sagi4, M. Fischer4, D. Hudesman9, S. Chang9, D. Lukin5, K. Sultan10, A. Swaminath11, N. Gupta12, C.A. Siegel7, B. Shen2, W.J. Sandborn3, B.E. Sands1, J.-F. Colombel1, S. Kane6, E.V. Loftus6, P.S. Dulai3*

Created: Thursday, 21 February 2019, 9:14 AM
OP026: The TOPPIC Trial: a randomised, double-blind parallel-group trial of mercaptopurine versus placebo to prevent recurrence of Crohns disease following surgical resection in 240 patients
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

I. Arnott1, C. Mowat2, H. Ennis3, C. Keerie3, S. Lewis3, N. Kennedy4, A. Cahill5, A. Morris5, M. Dunlop6, S. Bloom7, J. Lindsay8, S. Subramanian9, J. Satsangi*4, TOPPIC Trial Study Group10

Created: Friday, 22 February 2019, 9:49 AM
OP026: Zero diagnostic yield of dysplasia in polyp adjacent biopsies for patients with Inflammatory Bowel Disease
Year: 2017
Source: ECCO'17 Barcelona
Authors: Lahiff C.
Last Modified: Wednesday, 15 March 2017, 2:21 PM by ECCO Administrator
Colonoscopic surveillance, Chromoendoscopy, Colonoscopy, Dysplasia, UC colorectal cancer surveillance
Files: 1
OP026: Zero diagnostic yield of dysplasia in polyp adjacent biopsies for patients with inflammatory bowel disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Lahiff C.*1, Wang L.M.2, Travis S.P.L.1, East J.E.1

Created: Wednesday, 20 February 2019, 10:36 AM
OP027: Anti-tumour necrosis factor therapy is associated with increased risk of postoperative morbidity after surgery for ileocolonic Crohns disease: outcome analysis in a prospective nationwide cohort of 592 patients conducted by the GETAID chirurgie group
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

A. Brouquet*1, L. Maggiori2, P. Zerbib3, J. Lefèvre4, Q. Denost5, A. Germain6, E. Cotte7, L. Beyer-Berjot8, N. Munoz-Bongrand9, V. Desfourneaux10, A. Rahili11, J.-P. Duffas12, K. Pautrat13, C. Denet14, V. Bridoux15, G. Meurette16, J.-L. Faucheron17, J. Loriau18, F. Guillon19, E. Vicaut20, S. Benoist1, Y. Panis2

Created: Friday, 22 February 2019, 9:49 AM
OP027: IL-33/ST2 axis sustains gut mucosal wound healing and cancerogenesis in Colitis-associated colorectal cancer
Year: 2017
Source: ECCO'17 Barcelona
Authors: Lopetuso L.
Last Modified: Wednesday, 15 March 2017, 2:20 PM by ECCO Administrator
Epithelial cell, Fibroblast, Immunology
Files: 1
OP027: IL-33/ST2 axis sustains gut mucosal wound healing and cancerogenesis in colitis-associated colorectal cancer
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Lopetuso L.R.*1,2, De Salvo C.3, Di Martino L.3, Goodman W.3, Scaldaferri F.4, Gasbarrini A.4, Pizarro T.T.3

Created: Wednesday, 20 February 2019, 10:36 AM
OP027: SUCNR1 receptor mediates intestinal fibrosis
Year: 2018
Source: ECCO '18 Vienna
Authors:

J. Cosin-Roger1,2*, D. Ortiz-Masia2, D.C. Macias-Ceja1, L. Gisbert-Ferrandiz2, P. Salvador2, M. Hausmann3, G. Rogler3, S. Calatayud2, M.D. Barrachina2

Created: Thursday, 21 February 2019, 9:14 AM
OP027: SUCNR1 receptor mediates intestinal fibrosis
Year: 2018
Source: ECCO'18 Vienna
Authors: Cosin-Roger Jesus
Created: Friday, 23 March 2018, 12:23 PM
Files: 1
OP028: Gut specific regulatory T cells – a new frontier for Crohn's disease therapy
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Goldberg R.*1,2,3,4, Scotta C.3,4,5, Cooper D.6, Eliraz E.7, Nir E.7, Irving P.1,8, Sanderson J.1,8, Shpigel N.7, Marelli-Berg F.6, Lombardi G.3,4,5, Lord G.2,3,4

Created: Wednesday, 20 February 2019, 10:36 AM
OP028: Gut specific regulatory T cells – a new frontier for Crohn’s Disease therapy
Year: 2017
Source: ECCO'17 Barcelona
Authors: Goldberg R.
Last Modified: Wednesday, 15 March 2017, 2:18 PM by ECCO Administrator
Immunology, Lymphocyte,T Cell
Files: 1
OP028: Pharmacokinetics and exposure-response relationships of intravenously administered ustekinumab during induction treatment in patients with Crohns disease: results from the UNITI-1 and UNITI-2 studies
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

O. J. Adedokun*1, Z. Xu1, C. Gasink1, J. Friedman1, P. Szapary1, Y. Lang1, J. Johanns1, L.-L. Gao1, Y. Miao1, H. Davis1, S. Hanauer2, B. Feagan3, W. Sandborn4

Created: Friday, 22 February 2019, 9:49 AM
OP028: Single cell RNA sequencing of t-cells in Crohn’s disease identifies tissue specific drug targets
Year: 2018
Source: ECCO '18 Vienna
Authors:

E. Festen1*, R. Weersma1, W.T. Uniken Venema1, M.D. Voskuil1, D. Graham2

Created: Thursday, 21 February 2019, 9:14 AM
OP029: Characterisation of Paneth cell dysfunction in XIAP-deficient mice
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Yabal1*, A. Wahida1, B. Popper2, K. Steiger3, P. Jost1

Created: Thursday, 21 February 2019, 9:14 AM
OP029: Drug-concentration versus symptom-driven dose adaptation of Infliximab in patients with active Crohns disease: a prospective, randomised, multicentre trial (Tailorix)
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

G. D’Haens*1, S. Vermeire2, G. Lambrecht3, F. Baert4, P. Bossuyt5, M. Nachury6, A. Buisson7, Y. Bouhnik8, J. Filippi9, J. vande Woude10, P. Van Hootegem11, J. Moreau12, E. Louis13, D. Franchimont14, M. De Vos15, F. Mana16, L. Peyrin-Biroulet17, H. Brixi18, M. Allez19, P. Caenepeel20, A. Aubourg21, B. Oldenburg22, M. Pierik23, A. Gils24, S. Chevret25, D. Laharie26

Created: Friday, 22 February 2019, 9:49 AM